Redo-TAVI与accurate平台短框架经导管心脏瓣膜失效。

IF 9.5 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Eurointervention Pub Date : 2025-09-15 DOI:10.4244/EIJ-D-25-00255

Giuseppe Tarantini, Won-Keun Kim, Gerrit Kaleschke, Andreas Holzamer, Norman Mangner, Radoslaw Parma, Francesco Cardaioli, Luca Nai Fovino

{"title":"Redo-TAVI与accurate平台短框架经导管心脏瓣膜失效。","authors":"Giuseppe Tarantini, Won-Keun Kim, Gerrit Kaleschke, Andreas Holzamer, Norman Mangner, Radoslaw Parma, Francesco Cardaioli, Luca Nai Fovino","doi":"10.4244/EIJ-D-25-00255","DOIUrl":null,"url":null,"abstract":"Editorial note: On 28 May 2025, the manufacturer announced the global discontinuation of sales of its ACURATE neo2 and ACURATE Prime aortic valve systems. The following correspondence, submitted and accepted prior to the market withdrawal, discusses clinical experience with this device. Though no longer relevant for current practice, the Editorial Board believes it is important to document these findings in the interest of transparency and completeness of the scientific record. Accordingly, we are publishing this work as a Research Correspondence, with acknowledgement of the device's discontinued status.","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 18","pages":"e1102-e1105"},"PeriodicalIF":9.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418105/pdf/","citationCount":"0","resultStr":"{\"title\":\"Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves.\",\"authors\":\"Giuseppe Tarantini, Won-Keun Kim, Gerrit Kaleschke, Andreas Holzamer, Norman Mangner, Radoslaw Parma, Francesco Cardaioli, Luca Nai Fovino\",\"doi\":\"10.4244/EIJ-D-25-00255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Editorial note: On 28 May 2025, the manufacturer announced the global discontinuation of sales of its ACURATE neo2 and ACURATE Prime aortic valve systems. The following correspondence, submitted and accepted prior to the market withdrawal, discusses clinical experience with this device. Though no longer relevant for current practice, the Editorial Board believes it is important to document these findings in the interest of transparency and completeness of the scientific record. Accordingly, we are publishing this work as a Research Correspondence, with acknowledgement of the device's discontinued status.\",\"PeriodicalId\":54378,\"journal\":{\"name\":\"Eurointervention\",\"volume\":\"21 18\",\"pages\":\"e1102-e1105\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418105/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurointervention\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4244/EIJ-D-25-00255\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurointervention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4244/EIJ-D-25-00255","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

编者按：2025年5月28日，该制造商宣布在全球停止销售其accurate neo2和accurate Prime主动脉瓣系统。以下是在市场退出之前提交和接受的通信，讨论了使用该设备的临床经验。虽然与目前的实践不再相关，但编辑委员会认为，为了科学记录的透明度和完整性，将这些发现记录下来是很重要的。因此，我们将这项工作作为研究通信发表，并承认该设备的停产状态。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves.

Editorial note: On 28 May 2025, the manufacturer announced the global discontinuation of sales of its ACURATE neo2 and ACURATE Prime aortic valve systems. The following correspondence, submitted and accepted prior to the market withdrawal, discusses clinical experience with this device. Though no longer relevant for current practice, the Editorial Board believes it is important to document these findings in the interest of transparency and completeness of the scientific record. Accordingly, we are publishing this work as a Research Correspondence, with acknowledgement of the device's discontinued status.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurointervention CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

10.30

自引率

4.80%

发文量

380

审稿时长

3-8 weeks

期刊介绍： EuroIntervention Journal is an international, English language, peer-reviewed journal whose aim is to create a community of high quality research and education in the field of percutaneous and surgical cardiovascular interventions.